BiotechTube

PXL065

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ALD (Adrenoleukodystrophy)

Conditions

ALD (Adrenoleukodystrophy)

Trial Timeline

Sep 1, 2023 → Sep 1, 2024

NCT ID
NCT05200104

About PXL065

PXL065 is a phase 2 stage product being developed by Poxel for ALD (Adrenoleukodystrophy). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05200104. Target conditions include ALD (Adrenoleukodystrophy).

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05200104Phase 2Withdrawn

Other Products from Poxel

Imeglimin + PlaceboPhase 2
44
PXL770Phase 2
44
PXL770 + Placebo Oral CapsulePhase 2
44
PXL065 + Placebo oral tabletPhase 2
44
14C labeled PXL770Phase 1
25